Stem cell transplantation technology developer Magenta Therapeutics has closed a $50m series B round led by GV that included Access Industries and Partners Healthcare.

GV, a corporate venturing subsidiary of internet and technology conglomerate Alphabet, led a $50m round for US-based stem cell transplantation technology developer Magenta Therapeutics on Tuesday.

The round also featured conglomerate Access Industries and Partners Innovation Fund, the VC representative of care provider Partners Healthcare, as well as Atlas Venture, Third Rock Ventures, Casdin Capital and Be The Match BioTherapies, an investment arm of the National Marrow Donor Program.

Magenta is working on therapies for patients suffering from immune and…